The U.S. and New Zealand are the only two countries in the world that allow direct-to-consumer advertising of prescription drugs. (Photo: A./flickr/cc)
Nov 17, 2015
In an attempt to combat the soaring cost of prescription drugs and Big Pharma's stranglehold on the U.S. healthcare system, the American Medical Association (AMA) has approved a new policy to "support a ban on direct-to-consumer advertising for prescription drugs and implantable medical devices."
"Today's vote in support of an advertising ban reflects concerns among physicians about the negative impact of commercially-driven promotions, and the role that marketing costs play in fueling escalating drug prices," said AMA board chair-elect Patrice Harris, M.D., in a press statement on Tuesday. The vote took place at the AMA's 2015 Interim Meeting in Atlanta.
Supporters of the ban also cited concerns including patient confusion and encouragement of off-label, or unapproved, use of certain drugs.
The AMA points out that the U.S. and New Zealand are the only two countries in the world that allow direct-to-consumer advertising of prescription drugs. What's more, advertising dollars spent by drug makers have increased by 30 percent in the last two years to $4.5 billion, according to the market research firm Kantar Media.
And in the past few years, prices on generic and brand-name prescription drugs have steadily risen, experiencing a 4.7 percent spike in 2015 alone, according to the Altarum Institute Center for Sustainable Health Spending.
Though the move is largely symbolic, as any such ban would have to be authorized by Congress, the AMA plans to pull out all the stops in an effort to sway federal regulators, elected officials, and the public at-large.
To that end, the policy approved Tuesday calls for convening a physician task force and launching an advocacy campaign to promote prescription drug affordability by demanding choice and competition in the pharmaceutical industry, and greater transparency in prescription drug prices and costs. It also states that the AMA will now monitor pharmaceutical company mergers and acquisitions, as well as the impact of such actions on drug prices.
"By casting the issue in the context of rising drug prices, the AMA is clearly trying to create as much support as possible for a ban," wrote Ed Silverman for the health, medicine, and science publication STAT. "The cost of pharmaceuticals, after all, is a hot-button issue that has galvanized much of the American public in recent months. The AMA proposal amounts to yet another indication that drug pricing will remain a policy issue for the near-term."
Indeed, prescription drug prices have already become a presidential campaign issue, with everyone from Bernie Sanders and Hillary Clinton to Marco Rubio and Ben Carson acknowledging that healthcare costs are a top concern for American voters. In a separate piece for STAT, also published Tuesday, Silverman pointed to a new poll which finds that "91 percent of voters believe it's important for presidential candidates to hold down rising prescription drug costs."
As noted by the Chicago Tribune, the AMA is merely the latest health organization to call for a ban on such ads, following the World Health Organization, the National Center for Health Research, and other groups. Many consumer advocacy organizations, including Public Citizen, have also pushed for a ban, saying such advertising pressures doctors to prescribe particular medications that may be less effective and more expensive and risky.
On Tuesday, Public Citizen said it supports the AMA's call. In an email to Common Dreams, Michael Carome, M.D. and director of the group's Health Research division, stated: "We agree that such advertising is primarily promotional, not educational, and drives up the cost of drugs."
Join Us: News for people demanding a better world
Common Dreams is powered by optimists who believe in the power of informed and engaged citizens to ignite and enact change to make the world a better place. We're hundreds of thousands strong, but every single supporter makes the difference. Your contribution supports this bold media model—free, independent, and dedicated to reporting the facts every day. Stand with us in the fight for economic equality, social justice, human rights, and a more sustainable future. As a people-powered nonprofit news outlet, we cover the issues the corporate media never will. |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Deirdre Fulton
Deirdre Fulton is a former Common Dreams senior editor and staff writer. Previously she worked as an editor and writer for the Portland Phoenix and the Boston Phoenix, where she was honored by the New England Press Association and the Association of Alternative Newsweeklies. A Boston University graduate, Deirdre is a co-founder of the Maine-based Lorem Ipsum Theater Collective and the PortFringe theater festival. She writes young adult fiction in her spare time.
In an attempt to combat the soaring cost of prescription drugs and Big Pharma's stranglehold on the U.S. healthcare system, the American Medical Association (AMA) has approved a new policy to "support a ban on direct-to-consumer advertising for prescription drugs and implantable medical devices."
"Today's vote in support of an advertising ban reflects concerns among physicians about the negative impact of commercially-driven promotions, and the role that marketing costs play in fueling escalating drug prices," said AMA board chair-elect Patrice Harris, M.D., in a press statement on Tuesday. The vote took place at the AMA's 2015 Interim Meeting in Atlanta.
Supporters of the ban also cited concerns including patient confusion and encouragement of off-label, or unapproved, use of certain drugs.
The AMA points out that the U.S. and New Zealand are the only two countries in the world that allow direct-to-consumer advertising of prescription drugs. What's more, advertising dollars spent by drug makers have increased by 30 percent in the last two years to $4.5 billion, according to the market research firm Kantar Media.
And in the past few years, prices on generic and brand-name prescription drugs have steadily risen, experiencing a 4.7 percent spike in 2015 alone, according to the Altarum Institute Center for Sustainable Health Spending.
Though the move is largely symbolic, as any such ban would have to be authorized by Congress, the AMA plans to pull out all the stops in an effort to sway federal regulators, elected officials, and the public at-large.
To that end, the policy approved Tuesday calls for convening a physician task force and launching an advocacy campaign to promote prescription drug affordability by demanding choice and competition in the pharmaceutical industry, and greater transparency in prescription drug prices and costs. It also states that the AMA will now monitor pharmaceutical company mergers and acquisitions, as well as the impact of such actions on drug prices.
"By casting the issue in the context of rising drug prices, the AMA is clearly trying to create as much support as possible for a ban," wrote Ed Silverman for the health, medicine, and science publication STAT. "The cost of pharmaceuticals, after all, is a hot-button issue that has galvanized much of the American public in recent months. The AMA proposal amounts to yet another indication that drug pricing will remain a policy issue for the near-term."
Indeed, prescription drug prices have already become a presidential campaign issue, with everyone from Bernie Sanders and Hillary Clinton to Marco Rubio and Ben Carson acknowledging that healthcare costs are a top concern for American voters. In a separate piece for STAT, also published Tuesday, Silverman pointed to a new poll which finds that "91 percent of voters believe it's important for presidential candidates to hold down rising prescription drug costs."
As noted by the Chicago Tribune, the AMA is merely the latest health organization to call for a ban on such ads, following the World Health Organization, the National Center for Health Research, and other groups. Many consumer advocacy organizations, including Public Citizen, have also pushed for a ban, saying such advertising pressures doctors to prescribe particular medications that may be less effective and more expensive and risky.
On Tuesday, Public Citizen said it supports the AMA's call. In an email to Common Dreams, Michael Carome, M.D. and director of the group's Health Research division, stated: "We agree that such advertising is primarily promotional, not educational, and drives up the cost of drugs."
Deirdre Fulton
Deirdre Fulton is a former Common Dreams senior editor and staff writer. Previously she worked as an editor and writer for the Portland Phoenix and the Boston Phoenix, where she was honored by the New England Press Association and the Association of Alternative Newsweeklies. A Boston University graduate, Deirdre is a co-founder of the Maine-based Lorem Ipsum Theater Collective and the PortFringe theater festival. She writes young adult fiction in her spare time.
In an attempt to combat the soaring cost of prescription drugs and Big Pharma's stranglehold on the U.S. healthcare system, the American Medical Association (AMA) has approved a new policy to "support a ban on direct-to-consumer advertising for prescription drugs and implantable medical devices."
"Today's vote in support of an advertising ban reflects concerns among physicians about the negative impact of commercially-driven promotions, and the role that marketing costs play in fueling escalating drug prices," said AMA board chair-elect Patrice Harris, M.D., in a press statement on Tuesday. The vote took place at the AMA's 2015 Interim Meeting in Atlanta.
Supporters of the ban also cited concerns including patient confusion and encouragement of off-label, or unapproved, use of certain drugs.
The AMA points out that the U.S. and New Zealand are the only two countries in the world that allow direct-to-consumer advertising of prescription drugs. What's more, advertising dollars spent by drug makers have increased by 30 percent in the last two years to $4.5 billion, according to the market research firm Kantar Media.
And in the past few years, prices on generic and brand-name prescription drugs have steadily risen, experiencing a 4.7 percent spike in 2015 alone, according to the Altarum Institute Center for Sustainable Health Spending.
Though the move is largely symbolic, as any such ban would have to be authorized by Congress, the AMA plans to pull out all the stops in an effort to sway federal regulators, elected officials, and the public at-large.
To that end, the policy approved Tuesday calls for convening a physician task force and launching an advocacy campaign to promote prescription drug affordability by demanding choice and competition in the pharmaceutical industry, and greater transparency in prescription drug prices and costs. It also states that the AMA will now monitor pharmaceutical company mergers and acquisitions, as well as the impact of such actions on drug prices.
"By casting the issue in the context of rising drug prices, the AMA is clearly trying to create as much support as possible for a ban," wrote Ed Silverman for the health, medicine, and science publication STAT. "The cost of pharmaceuticals, after all, is a hot-button issue that has galvanized much of the American public in recent months. The AMA proposal amounts to yet another indication that drug pricing will remain a policy issue for the near-term."
Indeed, prescription drug prices have already become a presidential campaign issue, with everyone from Bernie Sanders and Hillary Clinton to Marco Rubio and Ben Carson acknowledging that healthcare costs are a top concern for American voters. In a separate piece for STAT, also published Tuesday, Silverman pointed to a new poll which finds that "91 percent of voters believe it's important for presidential candidates to hold down rising prescription drug costs."
As noted by the Chicago Tribune, the AMA is merely the latest health organization to call for a ban on such ads, following the World Health Organization, the National Center for Health Research, and other groups. Many consumer advocacy organizations, including Public Citizen, have also pushed for a ban, saying such advertising pressures doctors to prescribe particular medications that may be less effective and more expensive and risky.
On Tuesday, Public Citizen said it supports the AMA's call. In an email to Common Dreams, Michael Carome, M.D. and director of the group's Health Research division, stated: "We agree that such advertising is primarily promotional, not educational, and drives up the cost of drugs."
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.